These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31839407)

  • 1. Chemotherapy after progression on nivolumab is essential for responders with genetic alterations of driver gene: Review of two recurrent/metastatic oral squamous cell carcinoma patients.
    Ogi K; Kobayashi J; Nakagaki T; Okamoto J; Koike K; Hirokawa N; Someya M; Sakamoto H; Takada K; Tokino T; Sasaki Y; Hiratsuka H; Miyazaki A
    Oral Oncol; 2020 Mar; 102():104509. PubMed ID: 31839407
    [No Abstract]   [Full Text] [Related]  

  • 2. Progression beyond nivolumab: Stop or repeat? Dramatic responses with salvage chemotherapy.
    Daste A; De-Mones E; Cochin V; Dupin C; Digue L; Ravaud A; Domblides C
    Oral Oncol; 2018 Jun; 81():116-118. PubMed ID: 29703607
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Saleh K; Daste A; Martin N; Pons-Tostivint E; Auperin A; Herrera-Gomez RG; Baste-Rotllan N; Bidault F; Guigay J; Le Tourneau C; Saada-Bouzid E; Even C
    Eur J Cancer; 2019 Nov; 121():123-129. PubMed ID: 31574417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of chemotherapy after progression with nivolumab in squamous cell carcinoma of the head and neck.
    Suzuki S; Toyoma S; Tomizawa H; Yamada T; Iikawa N; Shiina K; Saito H; Koizumi K; Kawasaki Y; Yamada T
    Auris Nasus Larynx; 2020 Jun; 47(3):485-488. PubMed ID: 31248647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma.
    Fushimi C; Okamoto I; Matsuki T; Masubuchi T; Okada T; Sato H; Tsukahara K; Kondo T; Yamashita T; Hanyu K; Omura GO; Takahashi H; Tada Y; Miura K
    Anticancer Res; 2020 Sep; 40(9):5277-5283. PubMed ID: 32878817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with recurrent oral squamous cell carcinoma treated with nivolumab.
    Tachinami H; Tomihara K; Yamada SI; Ikeda A; Imaue S; Hirai H; Nakai H; Sonoda T; Kurohara K; Yoshioka Y; Hasegawa T; Naruse T; Niiyama T; Shimane T; Ueda M; Yanamoto S; Akashi M; Umeda M; Kurita H; Miyazaki A; Arai N; Hayashi R; Noguchi M
    Br J Oral Maxillofac Surg; 2023 May; 61(4):320-326. PubMed ID: 37061418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
    Zargar M; McFarlane T; Chan KKW; Wong WWL
    Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
    Haddad R; Concha-Benavente F; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Kasper S; Vokes EE; Worden F; Saba NF; Tahara M; Jayaprakash V; Lynch M; Li L; Gillison ML; Harrington KJ; Ferris RL
    Cancer; 2019 Sep; 125(18):3208-3218. PubMed ID: 31246283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-based efficacy and safety of nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter retrospective study.
    Kondo T; Okamoto I; Sato H; Koyama N; Fushimi C; Okada T; Masubuchi T; Miura K; Matsuki T; Yamashita T; Omura G; Takahashi H; Tsukahara K
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):340-347. PubMed ID: 32573033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab in squamous cell carcinoma of the head and neck.
    Specenier P
    Expert Rev Anticancer Ther; 2018 May; 18(5):409-420. PubMed ID: 29560755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
    Saada-Bouzid E; Peyrade F; Guigay J
    Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    El Rassy E; Assi T; Bakouny Z; El Karak F; Pavlidis N; Ghosn M
    Future Oncol; 2019 Mar; 15(8):909-923. PubMed ID: 30669875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment sequence of cetuximab and immune checkpoint inhibitor in head and neck squamous cell carcinoma differentially affects outcomes.
    Park JC; Durbeck J; Clark JR; Faden DL
    Oral Oncol; 2020 Dec; 111():105024. PubMed ID: 33065374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer.
    Suzuki C; Kiyota N; Imamura Y; Rikitake J; Sai S; Koyama T; Hyogo Y; Nagatani Y; Funakoshi Y; Toyoda M; Otsuki N; Nibu KI; Minami H
    Int J Clin Oncol; 2020 Jul; 25(7):1270-1277. PubMed ID: 32277393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter retrospective study of nivolumab for recurrent/metastatic oral squamous cell carcinoma.
    Yamakawa N; Umeda M; Yoshii Y; Mitsudo K; Noguchi M; Kusukawa J; Katakura A; Nakayama H; Sasaki M; Noguchi T; Ueda M; Bukawa H; Yagihara K; Horie A; Miyazaki A; Chikazu D; Tomihara K; Mishima K; Otsuru M; Asoda S; Fujiwara S; Ohyama Y; Kurita H; Kawamata H; Fukuda M; Shintani Y; Kobayashi T; Kanno T; Oh-Iwa I; Kawano K; Yamashita Y; Kobayashi W; Ohiro Y; Uzawa K; Ota Y; Kirita T
    Oral Dis; 2024 Mar; 30(2):247-258. PubMed ID: 36519515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [First report on successful application of nivolumab in Hungary for the treatment of locally recurrent head and neck squamous cell carcinoma].
    Bellyei S; Bakó P; Orosz É; Molnár K; Remenár É; Mangel L
    Magy Onkol; 2018 Sep; 62(3):175-178. PubMed ID: 30256884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term disease control in a metastatic squamous cell carcinoma of the oral cavity treated with maintenance metronomic capecitabine.
    Muratori L; La Salvia A; Gorzegno G; Sperone P; Scagliotti GV
    J Oncol Pharm Pract; 2020 Jan; 26(1):240-243. PubMed ID: 31042137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
    Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
    Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic role of epiregulin/amphiregulin expression in recurrent/metastatic head and neck cancer treated with cetuximab.
    Kogashiwa Y; Inoue H; Kuba K; Araki R; Yasuda M; Nakahira M; Sugasawa M
    Head Neck; 2018 Nov; 40(11):2424-2431. PubMed ID: 30302873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.